BioSpecifics Technologies Corp
BioSpecifics Technologies — Investor Presentation (October 2013)
23 slides from BioSpecifics Technologies's investor presentation, Oct 17, 2013
Slide 1: Innovators in the development & commercialization of injectable collagenase
Innovators in the development & commercialization of INJECTABLE COLLAGENASE a : BioSpecifics October 2013
Slide 2: Forward-Looking Statements
Forward-Looking Statements This presentation includes “forward-looking statements” within the meaning of, and made pursuant to the safe harbor provisions of, the Private Securities Litigation Reform Act of 1995. All statements other than statements of historical fact are “forward looking statements”
Slide 3: Company Overview
Company Overview BioSpecifics is a profitable, commercial-stage injectable collagenase (XIAFLEX®) for a broad range of cli XIAFLEX Marketed for Dupuytren’s Contracture in US XIAFLEX for Peyronie’s Disease XIAFLEX Development in Four Additional Indications Research in New Potential Indications Ex-US
Slide 4: Vast Therapeutic Potential for XIAFLEX
Vast Therapeutic Potential for XIAFLEX XIAFLEX" (injectable collagenase) provides a first-in-class, minimally invasive nonsurgical treatment option for conditions and diseases caused by collagen accumulation where current treatment options are limited BioSpecifics has documented positive clinical re
Slide 5: Dupuytren's Contracture
XIAFLEX for Dupuytren’s Contracture Definition & Key Complications XIAFLEX is the First and Only Approved Nonsurgical Therapy XIAFLEX US Market Opportunity Focus on Sales Growth and Commercial Expansion Source: Auxilum Pharmaceuticals, Inc Formation of a collagen cord in the hand that causes one or
Slide 6: Dupuytren's Contracture
XIAFLEX for Dupuytren’s Contracture Multi-cord Label Expansion Study Underway Top-line data from multi-cord 725-patient study anticipated in 4Q13 Auxilium expects to file sBLA for XIAFLEX label expansion for multiple concurrent injections into same hand Based on positive top-line results from Phase
Slide 7: Dupuytren's Contracture
XIAFLEX for Dupuytren’s Contracture Data from Multiple Studies Presented at ASSH Collagenase Optimal Reduction of Dupuytren’s — Long-term Evaluation of Success Study (“CORDLESS”) Year 5 Data from CORDLESS Expected in 4Q13 Use of Local Anesthesia (LA) in Dupuytren’s Contracture Procedures Source: Aua
Slide 8: Deep Clinical Pipeline
XIAFLEX Deep Clinical Pipeline Dupuytren’s Contracture Peyronie’s Disease PDUFA Action Date is December 6, 2013 tee joulder *Canine : = Lipoma Top-line data expected in 4Q13 * puman Top-line data expected in 4Q13 ipoma cellulite n 40 *Uterine Preclinical Fibroids studies ongoing *BioSpecifics-manage
Slide 9: Peyronie's Disease
XIAFLEX for Peyronie’s Disease Upcoming PDUFA Date Definition & Key Complications XIAFLEX Has Potential to be Only Approved Nonsurgical Therapy XIAFLEX US Market Opportunity PDUFA Date and EU Application Source: Auxllum Pharmaceuticals, Inc. Excess of inelastic collagen causing penile curvature defo
Slide 10: Peyronie's Disease
XIAFLEX for Peyronie’s Disease Current Treatment Options Patients currently choose from four treatment modalities: Examples include dnvasive!Surgical plication, grafting, Procedures precthes Surgical Procedures Invasive Non- Surgical Verapamil Injection Procedures Non-Invasive Examples include Vitam
Slide 11: Peyronie's Disease
XIAFLEX for Peyronie’s Disease Positive Top-line Results from IMPRESS Phase III Trials IMPRESS’ | and II clinical trial design Two randomized (2:1 of 0.58 mg XIAFLEX or placebo) double-blind Phase Ill trials in over 800 patients at 64 sites in US and Australia, with 52-week follow up Two co-primary
Slide 12: Canine and Human Lipomas
XIAFLEX for Canine and Human Lipomas BioSpecifics-Managed Phase II Clinical Programs Encapsulated deposits of benign fatty tumors often detected as bulges under Definition & the skin that occur in both humans and dogs Key Complications The most common benign tumors found in humans and can be a serio
Slide 13: Canine Lipomas
XIAFLEX for Canine Lipomas Chien-804 Placebo-controlled Phase II Trial BioSpecifics conducting placebo-controlled, randomized Phase II trial for XIAFLEX in dogs with benign subcutaneous lipomas 32 dogs randomized, single injection 1:1 XIAFLEX to placebo Primary efficacy endpoint: Relative change in
Slide 14: Human Lipomas
XIAFLEX for Human Lipomas Dose Escalation Phase II Clinical Trial BioSpecifics conducting open label, dose escalation Phase II trial for humans with benign subcutaneous lipomas 14 patients at single center with single injection administered in 4 ascending dosage groups ranging from 0.058 mg to 0.44
Slide 15: Uterine Fibroids
XIAFLEX for Uterine Fibroids Preclinical Studies Ongoing and frequent urination Benign tumors with significant co- ia Definition & morbidities, which can include pain, cant 1 sae decreased fertility, increased rate of a= Key Complications miscarriage, heavy menstrual bleeding Ba vs Pr dicati for hys
Slide 16: Frozen Shoulder
XIAFLEX for Frozen Shoulder Initiation of Later Stage Trials Expected in 4Q13 Inflammation and thickening of shoulder Definition & capsule due to collagen accumulation, Key Complications Condition often limits the range of motion of the shoulder No FDA-approved pharmaceutical XIAFLEX Has Potential t
Slide 17: Frozen Shoulder — Statistically Significant
Frozen Shoulder — Statistically Significant XIAFLEX Dose Response in Phase Ila Study 60: | pao | A Comparisonta va Exercise Cohort a 3 e a 3 t) 240 & bao o | E20 ° : Al 510 4 nin 5 2 coe ag ae a a a” al ge gett eat gat XIAFLEX Source: Auxilium Pharmaceuticals, inc. Forward Flexion "Shoulder Abductio
Slide 18: Cellulite
XIAFLEX for Cellulite Phase II Trial Initiation Expected in 4Q13 Definition Significant Market Opportunity for XIAFLEX as First Nonsurgical Therapy Phase II Trial Initiation Expected in 4Q13 Skin dimpling as a result of collagen fibrous septae held in an irregular pattern under the skin, occurring m
Slide 19: Auxilium Partnership
Auxilium Partnership BioSpecifics is partnered with Auxilium for the development and commercialization of collagenase clostridium histolyticum (CCH) >$34M Received from Auxilium Future Payments Due to BioSpecifics from Auxilium Royalties from Potential Second Indication Auxilium Opt-In Rights Ex-US
Slide 20: Corporate Highlights
Corporate Highlights Strong Intellectual Property Portfolio Long-term patent protection for injectable collagenase: Dupuytren’s contracture: XIAFLEX has Orphan Drug protection in US until 2017; Drug product composition patent until 2028 and Biologic Exclusivity until 2022 Peyronie’s disease: Auxiliu
Slide 21: Consistently Profitable Annually
Consistently Profitable Annually 2Q13 Financial Highlights For the quarter For the year ended ended 06/30/13 12/31/12 (unaudited) (unaudited) Cash and equivalents, short term investments $s. 11,984,495, $ 8,503,737 Income Statement Revenues $ 3,269,983 $11,145,078 Other income 6,510 34,634 Costs and
Slide 22: Anticipated Upcoming Milestones
Anticipated Upcoming Milestones Significant Momentum for XIAFLEX in 4Q13 4Q13 Milestones Dupuytren’s Announce XIAFLEX 5-year recurrence data Contracture Multi-cord study top-line data Peyronie’s Disease Frozen Shoulder *Human Lipomas *Canine Lipomas Cellulite *Uterine Fibroids
Slide 23: Innovators in the development & commercialization of injectable collagenase
Innovators in the development & commercialization of INJECTABLE COLLAGENASE ee es, 7 BioSpecifics October 2013
BioSpecifics Technologies — Investor Presentation (October 2013) on 6ix